Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide

S. Hassanipour-Azgomi 1, Abdollah Mohammadian-Hafshejani 2, Mahshid Ghoncheh 3, Farhad Towhidi 4, Saeid Jamehshorani 4, Hamid Salehiniya 5, 6, *

1 Department of Epidemiology, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Social Medicine, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
3 Department of Epidemiology & Biostatistics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
4 Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
5 Zabol University of Medical Sciences, Zabol, Iran
6 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Article Info

Article history:
Received 2 February 2016
Received in revised form 7 May 2016
Accepted 18 July 2016
Available online 25 July 2016

Keywords:
Development
Incidence
Mortality
Prostate cancer

Abstract

Background: The aim of this study was to evaluate the incidence and mortality of prostate cancer and their relationship with the Human Development Index (HDI) and its components in Asia in 2012.

Methods: This study was an ecological study conducted based on the GLOBOCAN project of the World Health Organization. The correlation between standardized incidence rate (SIR) and standardized mortality rate (SMR) of prostate cancer with HDI and its components was assessed using SPSS Inc Version 18.0 (Chicago).

Results: There were 1,094,916 incident cases of prostate cancer and 307,481 deaths recorded in 2012 worldwide. SIR and SMR due to HDI were 72 and 9.7 in very high human development regions, 37.5 and 12.9 in high human development regions, 7 and 3.7 in medium human development regions, and 14.9 and 12.1 in low human development regions per 100,000 people, respectively. A positive correlation of 0.475 was seen between SIR of prostate cancer and HDI (P < 0.001). Also, a negative correlation of 0.160 was seen between SMR and HDI (P = 0.032).

Conclusion: The incidence of prostate cancer is high in countries with higher development. A positive correlation was observed between the SIR of prostate cancer and the HDI and its components, such as life expectancy at birth, mean years of schooling, and the gross national income per capita. In addition, there was a negative correlation between SMR and HDI.

Copyright © 2016 Asian Pacific Prostate Society, Published by Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Currently, cancer is one of the leading causes of death in many high-income countries. Prostate cancer is one of the most common cancers among men. Deaths from prostate cancer are second highest after deaths from lung cancer. The incidence and prevalence of prostate cancer vary in different parts of the world, with the highest in North America and the lowest in South Asia. It is estimated that 1.1 million men with prostate cancer were diagnosed in 2012 and 70% of them (795,000 cases) were in developed countries. The highest age-specific incidence rate in New Zealand and Australia is 111.6 per 100,000 and the lowest rate is in South Asia with a level of 4.5 per 100,000.

Several studies have shown that the incidence of prostate cancer in recent years has grown substantially. The increase in the incidence of prostate cancer could be due to greater access to prostate-specific antigen (PSA) diagnostic tests by communities and other factors such as lifestyle, nutrition, physical activity, environmental factors, and smoking. The PSA test that started in 1980 has caused a significant increase in the incidence of prostate cancer. Studies have shown that countries with higher social and economic levels have higher levels of prostate cancer; in contrast, prostate cancer is seen less often in countries with lower socioeconomic levels. It has been observed that incidence of this illness increases with age, and it is thought that the aging of the...
global population and increase in life expectancy will increase the incidence of this disease in the future.\textsuperscript{18–20}

The effect of aging in low- and middle-income countries is greater than in high-income countries. It is predicted that there will be 20.3 million new cases of prostate cancer in 2030 and that 13.2 million of them will not survive. In 2008, there were 12.7 million new cases, 7.6 million of these died.\textsuperscript{21}

Economic and social levels are known to affect the incidence and mortality of cancer.\textsuperscript{22} The Human Development Index (HDI) is a predictor of the economic and social level of different countries that can be associated with many diseases, including cancer.\textsuperscript{17,23–25}

Several studies have examined the role of the HDI and its relationship with the incidence and mortality of cancer.\textsuperscript{4,17,26} Due to the probable role of HDI in changing the incidence and prevalence of prostate cancer and the importance of knowledge about the incidence and prevalence of this disease in programming and performing etiology studies, and lack of an integrated worldwide study of HDI, this study investigated the standardized incidence rate (SIR) and standardized mortality rate (SMR) of prostate cancer and their relationship with HDI in 2012.

2. Materials and methods

2.1. Method for estimating age-specific incidence and mortality rates in the global cancer project by the international agency for research on cancer

This was a global ecologic study to assess the correlation between the age-specific incidence and mortality rate and the HDI, and its particulars, including life expectancy at birth, mean years of schooling, and gross national income per capita. Data about the age-specific incidence and mortality rates for every country in 2012 were obtained from the global cancer project (http://globocan.iarc.fr/Default.aspx),\textsuperscript{27} and the HDI from the Human Development Report 2013,\textsuperscript{28} which includes information about the HDI for every country in 2012.

2.2. Estimate of age-specific incidence rate

The methods of estimation are country specific, and the quality of the estimation depends upon the quality and amount of information available for each country. In theory, there are as many methods as countries, and because of the variety and the complexity of these methods, an overall quality score for the incidence and mortality estimates combined is almost impossible to establish. However, an alphanumeric scoring system that independently describes the availability of incidence and mortality data has been established at the country level. The combined score is presented together with the estimates for each country with the aim of providing a broad indication of the robustness of the estimation.

The methods to estimate the sex- and age-specific incidence rates of cancer for a specific country fall into one of the following broad categories, in priority order: (1) rates projected to 2012 (38 countries); (2) most recent rates applied to 2012 population (26 countries); (3) estimates from national mortality by modeling, using incidence mortality ratios derived from recorded data in country-specific cancer registries (13 countries); (4) estimates from national mortality estimates by modeling, using incidence mortality ratios derived from recorded data in local cancer registries in neighboring countries (nine European countries); (5) estimates from national mortality estimates using modeled survival (32 countries); (6) estimates as the weighted average of the local rates (16 countries); (7) one cancer registry covering a part of a country is used as representative of the country profile (11 countries); (8) age/sex specific rates for all cancers were partitioned using data on relative frequency of different cancers (by age and sex) (12 countries); and (9) rates are those of neighboring countries or registries in the same area (33 countries).\textsuperscript{27}

2.3. Estimate of age-specific mortality rate

Depending on the degree of detail and accuracy of the national mortality data, six methods have been utilized in the following order of priority: (1) rates projected to 2012 (69 countries); (2) most recent rates applied to 2012 population (26 countries); (3) estimates as the weighted average of regional rates (one country); (4) estimates from national incidence estimates by modeling, using country-specific survival (two countries); (5) estimates from national incidence estimates using modeled survival (83 countries); and (6) rates are those of neighboring countries or registries in the same area (three countries).\textsuperscript{27}

2.4. HDI

HDI is a composite measure of indicators along three components, including life expectancy, educational attainment, and command over the resources needed for a decent living. All groups and regions have seen notable improvement in all HDI components, with faster progress in low- and medium-HDI countries. On this basis, the world is becoming less unequal. Nevertheless, national averages hide large variations in human experience. Wide disparities remain within developing and developed countries and income inequality within and among many countries has been rising. According to the HDI, countries are divided into four categories: very high HDI ($>0.80$), high HDI ($0.80 >$ HDI $> 0.710$), medium HDI ($0.710 >$ HDI $> 0.535$), and low HDI ($<0.535$).\textsuperscript{28}

2.5. Statistical analysis

In this study, we used the correlation bivariate method for assessment of the correlation between age-specific incidence and mortality rate with HDI and its details, which include life expectancy at birth, mean years of schooling, and gross national income per capita. Statistical significance was assumed at $P < 0.05$. All reported $P$ values were two-sided. Statistical analyses were performed using SPSS Inc Version 18.0 (Chicago).

3. Results

In total, 1,094,916 cases of prostate cancer were recorded worldwide in 2012. The following 10 countries had the highest number of recent cases: United States (US) 233,159 cases; Brazil 72,536 cases; Germany 68,262 cases; France (metropolitan) 56,841 cases; Japan 55,970 cases; China 46,745 cases; United Kingdom 45,406 cases; Italy 44,525 cases; Spain 27,853 cases; and Canada 27,087. These countries account for 678,384 cases (61.95%) of the global total.

The following 10 countries had the highest SIR of prostate cancer: France 129.7 per 100,000 people; Martinique 123.1 per 100,000; Norway 227.2 per 100,000; Trinidad and Tobago 115.2 per 100,000; Barbados 123.9 per 100,000; Sweden and Ireland 114.6 per 100,000; Australia 119 per 100,000; New Caledonia 107.2 per 100,000; French Polynesia 114.9 per 100,000; and Switzerland 114.2 per 100,000. The following 10 countries had the lowest SIR of prostate cancer: Uzbekistan 1.7 per 100,000 people; Bhutan 1.2 per 100,000; Nepal 1.5 per 100,000; Uzbekistan 2.0 per 100,000; Turkmenistan 2.1 per 100,000; Tajikistan 2.3 per 100,000; Yemen with 2.7 per 100,000; Sri Lanka 3.0 per 100,000; North Korea 3.2 per 100,000; and 3.4 per 100,000.
The SIR due to HDI was 72 per 100,000 people in very high human development regions; 37.5 per 100,000 in high human development regions; 7.0 per 100,000 in medium human development regions; and 14.9 per 100,000 in low human development regions. Also, SIR was 58.5 per 100,000 people in the World Health Organization (WHO) Europe Region; 75 per 100,000 in the WHO Americas Region; 12.6 per 100,000 in the WHO Western Pacific Region; 9.7 per 100,000 in the WHO South-East Asia Region; and 26.8 per 100,000 in the WHO Africa Region. Also, it was 68 per 100,000 people in more-developed regions and 14.5 per 100,000 in less-developed areas.

The number of cases and crude SIR of prostate cancer in different regions of the world is shown in Table 1. Different parts of the world are sorted from high to low according to SIR. The highest and lowest standardized regions can be observed for each sex (Figs. 1 and Table 1).

In the year 2012, 307,481 deaths occurred from prostate cancer worldwide. Mortality was highest in the following 10 countries: US 30,383 cases; China 22,603 cases; Brazil 17,218 cases; Germany 16,181 cases; and Indonesia 919 cases; giving a total of 147,521 fatal cases (47.97%).

The following 10 countries had the highest SIR for prostate cancer: Trinidad and Tobago 58.9 per 100,000 people; Guyana 48.2 per 100,000; Barbados 45.6 per 100,000; Burundi 40.2 per 100,000; Jamaica 40.2 per 100,000; Uganda 38.8 per 100,000; Bahamas 36.6 per 100,000; Dominican Republic 34.6 per 100,000; Haiti 32.3 per 100,000; and Guinea 30.2 per 100,000. The following countries had the lowest SIR for prostate cancer: Bhutan 0.7 per 100,000 people; Nepal 1.2 per 100,000; Bangladesh 1.2 per 100,000; North Korea 1.3 per 100,000; Turkmenistan 1.5 per 100,000; Uzbekistan 1.5 per 100,000; Sri Lanka 1.6 per 100,000; Tajikistan 1.9 per 100,000; and Yemen 2.3 per 100,000.

SMR based on HDI was 9.7 per 100,000 people in very high human development regions; 12.9 per 100,000 in high human development regions; 3.7 per 100,000 in medium human development regions; and 12.1 per 100,000 in low human development regions. Also, SIR was 11.5 per 100,000 people in the WHO Europe Region; 13.1 per 100,000 in the WHO Americas Region; 3.5 per 100,000 in the WHO Western Pacific Region; 3.6 per 100,000 in the WHO South-East Asia Region; 6.2 per 100,000 in the WHO East...
Mediterranean Region; and 19.9 per 100,000 in the WHO Africa Region. SMR was 10.0 per 100,000 people in more-developed regions and 6.6 per 100,000 in less-developed regions (Figs. 1, 3 and Table 1).

3.1. SIR and HDI

A positive correlation of 0.475 was seen between SIR of prostate cancer and HDI and this correlation was statistically significant ($P < 0.001$) (Fig. 4). Also, there was a positive correlation between HDI components and SIR. Between SIR and life expectancy at birth, there was a positive correlation of 0.289 ($P < 0.001$); between SIR and mean education years, there was a positive correlation of 0.422 ($P < 0.001$); and between SIR and income level per person in the population, there was a positive correlation of 0.353 ($P < 0.001$).

Countries were classified according to HDI as follows: 47 in the very high human development category; 46 in the high human development category; 46 countries in the medium human development category; 44 countries in the low human development category; 44 countries in the very low human development category.

![Fig. 1. Standardized incidence and mortality rate of prostate cancer worldwide in 2012. ASR (W), age-standardised rate (world).](image-url)

![Fig. 2. Geographical distribution of prostate cancer incidence rate worldwide in 2012 (extracted from GLOBOCAN 2012). ASR, age-standardised rate.](image-url)
development category; and 8 countries in the unknown category. Table 2 shows the numbers that were related to HDI and their components.

3.2. SMR and HDI

There was a negative correlation of 0.160 between SMR for prostate cancer and HDI and it was statistically significant ($P = 0.032$) (Fig. 5). Also, correlations were observed between HDI components and standardized incidence. Between SMR and life expectancy at birth, there was a negative correlation of 0.155 ($P = 0.038$); between SMR and mean education years, there was a negative correlation of 0.120 ($P = 0.108$); and between income level per person in the population, there was a negative correlation of 0.109 ($P = 0.145$).

4. Discussion

The results of this study showed that the exclusive incidence rate of prostate cancer has a significant and direct relation with HDI worldwide. Also, all components of HDI (life expectancy at birth, education level, and income level) were related to the incidence of cancer. Countries like France and Norway that had the highest age-specific incidence and mortality rate of prostate cancer were counted as high HDI countries and countries such as Bhutan and Nepal that had the lowest incidence and mortality were counted as low HDI countries. Other studies have also shown higher incidence of prostate cancer in high HDI countries.4,17,29 The reasons may include diet, lifestyle, widespread clinical examinations, and most importantly, access to preventive services like PSA testing, and the presence of cancer registry systems in countries with higher HDI.

One of the human development components that had a positive and significant relation with incidence of prostate cancer in this study was life expectancy at birth. Studies have shown that prostate cancer has a close relationship with age, such that many cases occur in men aged >80 years.30 Those living in countries with a greater life expectancy relevant to the development indicators are more likely to have cancer, including prostate cancer.4,12 This is related to a decrease in communicable diseases and increase in treatment methods of other diseases, and as a result, enhancement of life expectancy and confrontation with old-age-related diseases like prostate cancer.13

Another component of human development is education and awareness. Results of this study showed that there was a significant positive association with prostate cancer incidence. People who have a higher education level have better diets, more physical activity, and are less affected by communicable diseases, and the chance of being affected by noncommunicable disease increases.
In a study performed in the US, the incidence of prostate cancer in educated men was greater than in the less educated population. In conclusion, the incidence of prostate cancer is higher in countries that are more developed. A positive correlation was observed between the SIR of prostate cancer and HDI and its components, such as life expectancy at birth, mean years of schooling, and income level per person of the population. In addition, there was a negative correlation between the SMR and HDI. Epidemiological transition is expected to occur in communities with increasing HDI and reduced incidence of infectious diseases and increased incidence of noncommunicable diseases such as cancer. However, although the incidence is high, the mortality rate is reduced, which represents an improvement of diagnosis and efficacy of treatment in prostate cancer patients with increasing levels of HDI.

Conflicts of interest
None declared.